ArticleBlood advances2020

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.

Stephen M Ansell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.